Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
Garadacimab's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for Garadacimab. Showing past 6 months and next 12 months · 18 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| Garadacimab | CSL Limited | Monoclonal antibody | Phase 3 | 0 | ||||
| Berotralstat Treatment in Children With Hereditary Angioedema | BioCryst Pharmaceuticals | — | Phase 3 |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE | Pharvaris Netherlands B.V. | — | Phase 3 | — | — | — | — | — |
| Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks | Octapharma | — | Phase 3 | — | — | — | — | — |
| A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) | Ionis Pharmaceuticals, Inc. | — | Phase 3 | — | — | — | — | — |
| Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency | Pharvaris Netherlands B.V. | — | Phase 3 | — | — | — | — | — |
| Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE | Pharvaris Netherlands B.V. | — | Phase 3 | — | — | — | — | — |
| Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies | BioCryst Pharmaceuticals | — | Phase 3 | — | — | — | — | — |